Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: 2 - The Real Truth

Developing new medicines for everyone, everywhere, equally

The pharmaceutical industry’s role as healer is sorely diminished if we don’t develop medicines fairly for everyone who needs them.

Fortune

Biden names 10 drugs for first negotiations to cut Medicare prices

Government claims prices could fall for 9m seniors but pharma companies claim cost-reduction program is unconstitutional

The Guardian - US

Rethinking auditing and transparency in the age of A.I.

In today’s world of increasing disclosures, such as ESG and cybersecurity, the responsibility of the internal audit continues to expand and has become even more critical.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

How health care leaders are leveraging technology in a tumultuous economy

Making health care accessible and equitable is the goal.

Fortune

3 factors driving health care inequality—and ideas for how we can solve it

'The rich get richer, and the poor get poorer. The same is true for health...The underserved get sicker.'

Fortune

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE:MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD). Merck shares traded in a range of $89.72 to $90.97 on day volume of 5.2…

Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study evaluating Abecma (idecabtagene vicleucel) compared to standard combination regimens in adults with multiple myeloma that is relapsed and refractory. Bristol Myers shares traded in a range of $73.95 to $75.32 on a day volume…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Benzinga

Recap Of Friday's Biotech Catalysts - End Of The Day Summary

Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…

Benzinga

'ESG' represents a fundamental shift in business strategy—but the term is unclear, unpopular, and increasingly polarizing

"Women's and family health has always been underserved," says Ryder.

Fortune

Merger Arbitrage Mondays – Bristol Myers (BMY) Acquires Third Point Therapeutics (TPTX)

Another week and another deal with big pharma buying out a development stage oncology company. Given the real synergies to be had through young companies partnering with big pharma to leverage their manufacturing expertise and distribution networks, regulators have allowed most of them to go through and they tend to…

Benzinga

Biotech buyout: San Diego's Turning Point Therapeutics sells to Bristol Myers Squibb for $4.1 billion

Bristol Myers Squibb has inked a deal to buy San Diego's Turning Point Therapeutics for $4.1 billion in cash, strengthening the pharmaceutical giant's presence in precision cancer treatments.

Tribune News Service

40 Stocks Moving In Friday's Mid-Day Session

Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.

Benzinga

BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology

BridgeBio Pharma Inc (NASDAQ:BBIO) has announced an exclusive license with Bristol Myers Squibb Co (NYSE:BMY) to develop and commercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology. Under the agreement terms, BridgeBio will receive an upfront payment of $90 million, up to $815 million in development, regulatory and sales milestone payments, and tiered royalties in…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Immatics Initiates Phase 1 Clinical Trial of IMA401 in Advanced Solid Tumors

Immatics N.V. (NASDAQ: IMTX) announced the initiation of a Phase 1 clinical trial of its drug candidate IMA401 for patients with recurrent and/or refractory solid tumors.

Benzinga

U.S. FDA Approves Bristol Myers Squibb's Camzyos™ (mavacamten) for the Treatment of Adults With obstructive HCM

Bristol Myers Squibb (NYSE: BMY) announced the U.S.

Benzinga

MindMed Appoints Francois Lilienthal As New CCO

With over twenty years of experience in the biopharmaceutical industry, Francois Lilienthal, MD, has joined Mind Medicine Inc. (NASDAQ:MNMD) as chief commercial officer (CCO). He had been serving as a consultant for the company for the last six months. Lilienthal has a long trajectory with pharmaceutical companies—in 1997, he was…

Benzinga

Bristol Myers Sues AstraZeneca Over PD-L1 Cancer Drug Patents

Bristol Myers Squibb Co (NYSE: BMY) claims that AstraZeneca Plc's (NASDAQ: AZN) PD-L1 inhibitor, Imfinzi, infringed on at least eight patents in a newly filed complaint.

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Bristol Myers Squibb is Soaring, and the Stock is Still Cheap

Bristol Myers Squibb's (BMY) outstanding clinical and operational performance, as well as the current momentum across its product portfolio, have enabled the biopharmaceutical concern to post stable revenue growth in its most recent quarterly earnings release. In addition, the stock is currently trading at a discounted valuation despite generating substantial…

Benzinga

CTI BioPharma's Bone Marrow Cancer Drug Scores FDA Approval

The FDA approved CTI BioPharma Corp's (NASDAQ:CTIC) Vonjo (pacritinib) for treating adult patients with myelofibrosis, a type of bone marrow cancer with low blood platelets count. Pacritinib is a JAK inhibitor and will compete with Incyte Corporation's (NASDAQ:INCY) Jakafi and Bristol Myers Squibb's Co (NYSE:BMY) Inrebic, which were approved in 2011 and 2019, respectively for myelofibrosis. CTI…

Benzinga

Bristol Myers Squibb's Mavacamten Aces Late-Stage Trial In Cardiomyopathy

Bristol Myers Squibb Co's (NYSE: BMY) VALOR-HCM Phase 3 study evaluating mavacamten in adults with obstructive hypertrophic cardiomyopathy (obstructive HCM)

StockNews.com

3 Warren Buffett Stocks to Buy in February: DaVita, Bristol Myers Squibb, and AbbVie

Warren Buffett’s value investing strategy has paid off, as its investment firm Berkshire Hathaway (BRK.A) has outperformed the broader market. Recently, the billionaire has become worther than Meta Platforms (FB) founder Mark Zuckerberg. Hence, we believe that the Berkshire Hathaway holdings AbbVie (ABBV), Bristol-Myers Squibb (BMY), and DaVita (DVA) might…

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.